Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lixte Biotechnology Holdings, Inc. - Common Stock (NQ:LIXT)

3.340 -0.060 (-1.76%)
Streaming Delayed Price Updated: 3:59 PM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lixte Biotechnology Holdings, Inc. - Common Stock

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Engages IBN to Support Corporate Communications Strategy
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks – Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Expands Ovarian Cancer Trial With MD Anderson and GSK
Via Investor Brand Network
Topics Intellectual Property
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’
Via Investor Brand Network
Topics Intellectual Property
BioMedNewsBreaks — Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) Announces $4.3 Million Registered Direct Offering Priced at Market
Via Investor Brand Network
Topics Intellectual Property
News headline image
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $4.3 Million Registered Direct Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities
Via ACCESS Newswire
News headline image
LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology
Via ACCESS Newswire
News headline image
LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers
Via ACCESS Newswire
News headline image
LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT)
Via ACCESS Newswire
News headline image
LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ:LIXT)
Via ACCESS Newswire
News headline image
24/7 Market News: LIXTE Holds the World's Only Clinical-Stage PP2A Inhibitor
Denver, Colorado--(Newsfile Corp. - September 5, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of... 
Via Newsfile
News headline image
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement
From Spartan Capital Securities, LLC
Via GlobeNewswire
News headline image
Lixte Biotechnology Holdings, Inc. to Present at August 20th Virtual Investor Summit Microcap Event
Via ACCESSWIRE
Lixte Biotechnology Holdings Inc. (NASDAQ: LIXT) Near Top of Volume Charts in Wednesday Trading
Via Investor Brand Network
News headline image
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
From Lixte Biotechnology Holdings, Inc.
Via GlobeNewswire
News headline image
WestPark Capital Announces Completion of $5.8 Million Registered Direct Offering Priced At-The-Market for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)
From WestPark Capital, Inc.
Via Business Wire
News headline image
Sidoti Microcap Virtual Conference
May 19 - 20, 2021 Presentation times and weblinks released for over 60 presenting companies NEW YORK, NY / ACCESSWIRE / May 18, 2021 / Sidoti & Company, LLC has released the presentation schedule and... 
From Sidoti & Company, LLC
Via AccessWire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.